HUM

Humana (HUM) reported 25% YoY premium growth in H1 2026 driven by Medicare Advantage membership expansion, with Insurance and CenterWell segments growing 24.5% and 21.2% respectively. However, the company faces headwinds from a 180 basis point increase in benefit ratio to 90.2% and a 26.1% surge in operating expenses. Competitors Elevance Health and Centene are also navigating challenges with elevated medical costs and declining government-sponsored membership.

UnitedHealth Group is prioritizing Chronic Special Needs Plans (C-SNPs) and Dual Eligible Special Needs Plans (D-SNPs) for 2027 to drive targeted Medicare Advantage growth. UNH expects Medicare margins near the upper end of its 2%-4% target in 2026, with at least 69% of its Medicare Advantage members in four-star or higher rated plans. The company faces competition from Humana and Centene, which are also expanding specialized Medicare Advantage offerings.

Humana Inc. (HUM) is forming a joint venture with BlackRock's HPS Investment Partners to own nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake valued at approximately $2.8 billion and hold majority ownership, while CenterWell retains minority ownership and operational control.

The partnership is expected to reduce Humana's balance sheet liabilities, provide greater financial flexibility, and accelerate clinic expansion. The transaction is set to close in Q4 2026 without materially affecting 2026 earnings guidance.

Humana shares surged 11.6% to $431.87, driven by strong Medicare membership growth (up 20.7% YoY to 17.9 million members) and expansion of its CenterWell platform. However, the stock faces headwinds as consensus EPS estimates have been revised 2.7% lower over the past 30 days, and the company is expected to report a quarterly loss of $1.04 per share. The stock holds a Zacks Rank #3 (Hold) rating.

UnitedHealth Group (UNH) and Humana (HUM) are compared as major players in U.S. managed healthcare. UNH benefits from its diversified Optum platform, improving Medicare Advantage profitability, and $1.5B AI investments, while HUM shows strong Medicare Advantage membership growth of 23.8% but faces margin pressures from rising benefit costs. UNH is rated as the more compelling investment with a Zacks Rank #2 (Buy) versus HUM's Rank #3 (Hold), offering 28.1% upside potential compared to HUM's 7.7%.

Centene Corporation is restructuring its Medicare Advantage business for 2027, pulling standard MA plans from 344 counties and exiting Hawaii, Oklahoma, and Tennessee due to unfavorable economics. The company is shifting focus toward Special Needs Plans and dual-eligible members while leveraging its Part D platform. Competitors UnitedHealth and Humana are also refining their MA footprints with similar selective approaches as medical and pharmacy costs pressure plan profitability.

OneTrust announced the winners of its 2026 TrustMaker Awards at TrustWeek, recognizing organizations excelling in responsible AI governance and data use. Fiserv, Workday, Humana, and Rockwell Automation were honored for their achievements in AI governance, operational excellence, impact, and overall trust leadership respectively. OneTrust also unveiled CORIE, a new platform innovation designed to govern AI agents at enterprise scale.

Centene Corporation (CNC) is set to report Q3 2026 earnings on Oct. 27 with projected EPS of 7 cents and revenues of $47.06B, both declining year-over-year. While the company benefits from improving Medicaid margins and Marketplace profitability, it faces headwinds from shrinking commercial and Medicaid memberships.

The stock has rallied 70.7% YTD but trades at elevated valuations relative to historical levels. Existing investors may hold positions while new investors should await better entry points.

UnitedHealth Group reported Q3 2026 earnings of $4.69 per share, beating consensus estimates of $4.12 and representing a 13.84% surprise. The company posted revenues of $112.69 billion, slightly exceeding expectations.

With a Zacks Rank #2 (Buy) rating, UnitedHealth has outperformed the S&P 500 by 0.6% year-to-date. However, the Medical - HMOs industry ranks in the bottom 24% of Zacks industries, which could impact future performance.

UnitedHealth Group is expected to report Q3 2026 earnings on October 13, 2026, with projected EPS growth of 41.1% to $4.12 per share, despite a 1.6% revenue decline to $111.38 billion. The company faces headwinds from declining memberships across commercial, Medicare Advantage, and Medicaid segments, but improved medical cost management and operational restructuring are expected to support margin expansion. UnitedHealth trades below its historical valuation median at 17.15X forward earnings, positioning it for potential recovery.

UnitedHealth Group heads into Q3 earnings with focus on whether its Q2 medical cost improvements can be sustained. The company improved its medical cost ratio to 86.7% in Q2, though $860 million in favorable reserve development aided results. Key questions include whether underlying medical costs remain stable and whether UnitedHealth can improve Medicare Advantage margins while managing expected membership losses of roughly 1.1 million members in 2025.

Dr. Aaron L. Schwartz, an assistant professor at the University of Pennsylvania, has been awarded the 2026 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award for his groundbreaking work on low-value care metrics and prior authorization research. His claims-based measures have been adopted by CMS for accountable care programs, and his research has influenced policy decisions at major healthcare organizations and government agencies.